K.E. Sherman

456 total citations
19 papers, 196 citations indexed

About

K.E. Sherman is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, K.E. Sherman has authored 19 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 7 papers in Epidemiology and 6 papers in Rheumatology. Recurrent topics in K.E. Sherman's work include Hepatitis C virus research (13 papers), Systemic Lupus Erythematosus Research (6 papers) and Liver Disease Diagnosis and Treatment (5 papers). K.E. Sherman is often cited by papers focused on Hepatitis C virus research (13 papers), Systemic Lupus Erythematosus Research (6 papers) and Liver Disease Diagnosis and Treatment (5 papers). K.E. Sherman collaborates with scholars based in United States, United Kingdom and Italy. K.E. Sherman's co-authors include Jason T. Blackard, Mark Sulkowski, Donald S. Williamson, Nathalie Adda, Mohamed Hashem, Tara L. Kieffer, G. Thomas Strickland, Sandra De Meyer, Ann M. Tigges and Samer S. El‐Kamary and has published in prestigious journals such as SHILAP Revista de lepidopterología, Hepatology and Journal of Hepatology.

In The Last Decade

K.E. Sherman

18 papers receiving 191 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.E. Sherman United States 8 163 136 57 18 12 19 196
M.J. Jimenez-Exposito Spain 7 258 1.6× 275 2.0× 91 1.6× 18 1.0× 11 0.9× 13 318
Neliswa Gogela United States 6 100 0.6× 101 0.7× 30 0.5× 9 0.5× 3 0.3× 9 129
J González Spain 6 264 1.6× 272 2.0× 96 1.7× 4 0.2× 8 0.7× 8 305
F Brun Spain 6 73 0.4× 79 0.6× 37 0.6× 4 0.2× 21 1.8× 10 147
A. Rivero Spain 5 219 1.3× 195 1.4× 68 1.2× 5 0.3× 11 0.9× 9 246
Sergio Veloso Spain 7 122 0.7× 121 0.9× 73 1.3× 12 0.7× 2 0.2× 10 199
K. Kaita Canada 7 161 1.0× 148 1.1× 31 0.5× 11 0.6× 9 0.8× 14 195
W Güthoff Germany 4 170 1.0× 170 1.3× 12 0.2× 14 0.8× 3 0.3× 5 196
Miguel Ángel Von-Wichmann Spain 2 232 1.4× 204 1.5× 80 1.4× 13 0.7× 2 0.2× 2 250
Luisa Roade Spain 9 108 0.7× 121 0.9× 17 0.3× 11 0.6× 13 1.1× 16 152

Countries citing papers authored by K.E. Sherman

Since Specialization
Citations

This map shows the geographic impact of K.E. Sherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.E. Sherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.E. Sherman more than expected).

Fields of papers citing papers by K.E. Sherman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.E. Sherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.E. Sherman. The network helps show where K.E. Sherman may publish in the future.

Co-authorship network of co-authors of K.E. Sherman

This figure shows the co-authorship network connecting the top 25 collaborators of K.E. Sherman. A scholar is included among the top collaborators of K.E. Sherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.E. Sherman. K.E. Sherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Sherman, K.E., Susan D. Rouster, Marion G. Peters, et al.. (2024). Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection. SHILAP Revista de lepidopterología. 9(2). 43–57.
2.
Blackard, Jason T. & K.E. Sherman. (2021). Drugs of Abuse and Their Impact on Viral Pathogenesis. Viruses. 13(12). 2387–2387. 12 indexed citations
3.
Rockstroh, JK, Karine Lacombe, Rolando M. Viani, et al.. (2017). Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study. Journal of Hepatology. 66(1). S102–S103. 16 indexed citations
4.
Reeves, Jacqueline D., Norah A. Terrault, Joseph K. Lim, et al.. (2016). Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Interim Analysis. Journal of Hepatology. 64(2). S187–S188. 3 indexed citations
5.
Sulkowski, Mark, Doug Dieterich, Anne F. Luetkemeyer, et al.. (2015). LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study. Journal of Hepatology. 62. S263–S263. 19 indexed citations
6.
7.
Sherman, K.E., Andrew J. Muir, Jyoti Aggarwal, et al.. (2013). 904 HEALTH-RELATED QUALITY-OF-LIFE AMONG GENOTYPE 1 TREATMENT-EXPERIENCED CHRONIC HEPATITIS C PATIENTS: POST-HOC ANALYSES FROM THE REALIZE STUDY. Journal of Hepatology. 58. S372–S372. 4 indexed citations
8.
Reddy, K. Rama, Adrian M. Di Bisceglie, Dorte Møller Jensen, et al.. (2013). 818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR. Journal of Hepatology. 58. S335–S335. 5 indexed citations
9.
Meyer, Sandra De, Doug J. Bartels, Inge Dierynck, et al.. (2011). 8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS. Journal of Hepatology. 54. S4–S4. 40 indexed citations
10.
11.
Tuthill, Cynthia, Shari N. Gordon, Paul J. Pockros, et al.. (2009). 647 TREATMENT OF HEPATITIS C WITH THE IMMUNE- STIMULATING DIPEPTIDE SCV-07. Journal of Hepatology. 50. S238–S238. 2 indexed citations
12.
13.
Shata, Mohamed Tarek M., Norah J. Shire, Sayed F. Abdelwahab, et al.. (2007). Characterization of hepatitis E-specific cell-mediated immune response using IFN-γ ELISPOT assay. Journal of Immunological Methods. 328(1-2). 152–161. 35 indexed citations
14.
Afdhal, Nezam H., Eliot Godofsky, M. Rodríguez‐Torres, et al.. (2006). 39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 results. Journal of Hepatology. 44. S19–S19. 27 indexed citations
15.
Sherman, K.E., Eric Lawitz, Christopher O’Brien, Eliot Godofsky, & Nathaniel Brown. (2006). O.078 Valopicitabine (NM283) plus peg-interferon for chronic hepatitis C in treatment naïve and nonresponder patients: interim phase IIb results. Journal of Clinical Virology. 36. S24–S24. 3 indexed citations
16.
Shire, Norah J., et al.. (2006). P.416 High prevalence of mixed HBV genotypes in patients with HIV. Journal of Clinical Virology. 36. S189–S189. 1 indexed citations
17.
18.
Simmons, Rebecca A., et al.. (1998). Cutaneous Necrosis Associated With Interferon α-2b. The American Journal of Gastroenterology. 93(3). 463–464. 5 indexed citations
19.
Williamson, Donald S., et al.. (1987). The Use of Semipermeable Dressings in Fingertip Injuries. Journal of Hand Surgery (European Volume). 12(1). 125–126. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.J. Jimenez-Exposito Breakdown of academic impact, for papers by Neliswa Gogela Breakdown of academic impact, for papers by J González Breakdown of academic impact, for papers by F Brun Breakdown of academic impact, for papers by A. Rivero Breakdown of academic impact, for papers by Sergio Veloso Breakdown of academic impact, for papers by K. Kaita Breakdown of academic impact, for papers by W Güthoff Breakdown of academic impact, for papers by Miguel Ángel Von-Wichmann Breakdown of academic impact, for papers by Luisa Roade
Rankless by CCL
2026